Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder

I. Fukui, H. Sekine, K. Kihara, T. Yamada, S. I. Takeuchi, M. Yokokawa, T. Kawai, K. Hosoda, F. Ohwada, S. Suzuki, H. Oshima, M. S. Soloway

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We treated 30 patients with carcinoma in situ of the bladder via intravesical combination chemotherapy. As an induction therapy 20 mg. mitomycin C on day 1 and 40 mg. doxorubicin on day 2 were instilled into the bladder once a week for 5 consecutive weeks. Patients who achieved complete response were assigned a maintenance instillation of mitomycin C alone every 2 to 4 weeks for 1 year. A total of 19 patients achieved complete response following an initial course of induction therapy and 2 partial responders to initial therapy also achieved complete response after repeated induction therapy, resulting in a 70 per cent over-all complete response rate. Toxicity was considerable with moderate to severe bladder irritation occurring in 20 patients but it was tolerable in the majority. Of 21 complete responses 13 remained free of disease for 6 to 43 months (average of 23 months), 5 had recurrent carcinoma in situ and 1 had invasive urethral cancer. In contrast, of 9 nonresponders 2 and 1 had invasive cancer of the bladder and ureter, respectively.

Original languageEnglish
Pages (from-to)531-534
Number of pages4
JournalJournal of Urology
Volume141
Issue number3 I
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Carcinoma in Situ
Mitomycin
Combination Drug Therapy
Doxorubicin
Urinary Bladder
Urethral Neoplasms
Ureteral Neoplasms
Therapeutics
Urinary Bladder Neoplasms
Maintenance

ASJC Scopus subject areas

  • Urology

Cite this

Fukui, I., Sekine, H., Kihara, K., Yamada, T., Takeuchi, S. I., Yokokawa, M., ... Soloway, M. S. (1989). Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. Journal of Urology, 141(3 I), 531-534.

Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. / Fukui, I.; Sekine, H.; Kihara, K.; Yamada, T.; Takeuchi, S. I.; Yokokawa, M.; Kawai, T.; Hosoda, K.; Ohwada, F.; Suzuki, S.; Oshima, H.; Soloway, M. S.

In: Journal of Urology, Vol. 141, No. 3 I, 01.01.1989, p. 531-534.

Research output: Contribution to journalArticle

Fukui, I, Sekine, H, Kihara, K, Yamada, T, Takeuchi, SI, Yokokawa, M, Kawai, T, Hosoda, K, Ohwada, F, Suzuki, S, Oshima, H & Soloway, MS 1989, 'Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder', Journal of Urology, vol. 141, no. 3 I, pp. 531-534.
Fukui I, Sekine H, Kihara K, Yamada T, Takeuchi SI, Yokokawa M et al. Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. Journal of Urology. 1989 Jan 1;141(3 I):531-534.
Fukui, I. ; Sekine, H. ; Kihara, K. ; Yamada, T. ; Takeuchi, S. I. ; Yokokawa, M. ; Kawai, T. ; Hosoda, K. ; Ohwada, F. ; Suzuki, S. ; Oshima, H. ; Soloway, M. S. / Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. In: Journal of Urology. 1989 ; Vol. 141, No. 3 I. pp. 531-534.
@article{b529b96fa2764120a551ffbc1ba3d5ab,
title = "Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder",
abstract = "We treated 30 patients with carcinoma in situ of the bladder via intravesical combination chemotherapy. As an induction therapy 20 mg. mitomycin C on day 1 and 40 mg. doxorubicin on day 2 were instilled into the bladder once a week for 5 consecutive weeks. Patients who achieved complete response were assigned a maintenance instillation of mitomycin C alone every 2 to 4 weeks for 1 year. A total of 19 patients achieved complete response following an initial course of induction therapy and 2 partial responders to initial therapy also achieved complete response after repeated induction therapy, resulting in a 70 per cent over-all complete response rate. Toxicity was considerable with moderate to severe bladder irritation occurring in 20 patients but it was tolerable in the majority. Of 21 complete responses 13 remained free of disease for 6 to 43 months (average of 23 months), 5 had recurrent carcinoma in situ and 1 had invasive urethral cancer. In contrast, of 9 nonresponders 2 and 1 had invasive cancer of the bladder and ureter, respectively.",
author = "I. Fukui and H. Sekine and K. Kihara and T. Yamada and Takeuchi, {S. I.} and M. Yokokawa and T. Kawai and K. Hosoda and F. Ohwada and S. Suzuki and H. Oshima and Soloway, {M. S.}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "141",
pages = "531--534",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3 I",

}

TY - JOUR

T1 - Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder

AU - Fukui, I.

AU - Sekine, H.

AU - Kihara, K.

AU - Yamada, T.

AU - Takeuchi, S. I.

AU - Yokokawa, M.

AU - Kawai, T.

AU - Hosoda, K.

AU - Ohwada, F.

AU - Suzuki, S.

AU - Oshima, H.

AU - Soloway, M. S.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We treated 30 patients with carcinoma in situ of the bladder via intravesical combination chemotherapy. As an induction therapy 20 mg. mitomycin C on day 1 and 40 mg. doxorubicin on day 2 were instilled into the bladder once a week for 5 consecutive weeks. Patients who achieved complete response were assigned a maintenance instillation of mitomycin C alone every 2 to 4 weeks for 1 year. A total of 19 patients achieved complete response following an initial course of induction therapy and 2 partial responders to initial therapy also achieved complete response after repeated induction therapy, resulting in a 70 per cent over-all complete response rate. Toxicity was considerable with moderate to severe bladder irritation occurring in 20 patients but it was tolerable in the majority. Of 21 complete responses 13 remained free of disease for 6 to 43 months (average of 23 months), 5 had recurrent carcinoma in situ and 1 had invasive urethral cancer. In contrast, of 9 nonresponders 2 and 1 had invasive cancer of the bladder and ureter, respectively.

AB - We treated 30 patients with carcinoma in situ of the bladder via intravesical combination chemotherapy. As an induction therapy 20 mg. mitomycin C on day 1 and 40 mg. doxorubicin on day 2 were instilled into the bladder once a week for 5 consecutive weeks. Patients who achieved complete response were assigned a maintenance instillation of mitomycin C alone every 2 to 4 weeks for 1 year. A total of 19 patients achieved complete response following an initial course of induction therapy and 2 partial responders to initial therapy also achieved complete response after repeated induction therapy, resulting in a 70 per cent over-all complete response rate. Toxicity was considerable with moderate to severe bladder irritation occurring in 20 patients but it was tolerable in the majority. Of 21 complete responses 13 remained free of disease for 6 to 43 months (average of 23 months), 5 had recurrent carcinoma in situ and 1 had invasive urethral cancer. In contrast, of 9 nonresponders 2 and 1 had invasive cancer of the bladder and ureter, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0024590476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024590476&partnerID=8YFLogxK

M3 - Article

C2 - 2493099

AN - SCOPUS:0024590476

VL - 141

SP - 531

EP - 534

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3 I

ER -